Market Overview

UPDATE: Morgan Stanley Upgrades Catamaran to Overweight on Improved Fundamental Outlook

UPDATE: Morgan Stanley Reiterates Equal-Weight Rating on Catamaran Corp Following Salveo Acquisition
Catamaran To acquire Salveo Specialty Pharmacy For $260M In Cash

Morgan Stanley raised its rating on Catamaran (NASDAQ: CTRX) from Equal-weight to Overweight and established a $55 price target.

Morgan Stanley commented, "Deal synergies, share gains and up-selling specialty will lead to strong earnings growth. Acquisition pipeline, included in our bull case, can provide further support. … . Our Base case includes synergy timing modestly ahead of guidance, normalized share gains, and benefits from bringing specialty in-house. Our '13 EPS of $1.95 and '14 EPS of $2.40 compares to cons' $1.80 and $2.27."

Catamaran closed at $48.02 on Friday.

Latest Ratings for CTRX

Feb 2015Deutsche BankMaintainsHold
Feb 2015Leerink SwannMaintainsOutperform
Feb 2015BarclaysMaintainsEqualweight

View More Analyst Ratings for CTRX
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings


Related Articles (CTRX)

Around the Web, We're Loving...

Get Benzinga's Newsletters